Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Manzo Pharmaceuticals, Inc. (OTC: MNZO).

Full DD Report for MNZO

You must become a subscriber to view this report.


Recent News from (OTC: MNZO)

SEC Suspension of Trading
SEC Suspension of Trading
Source: OTC Markets
Date: March, 09 2018 00:00
New Manzo Pharmaceuticals, Inc. Website
New Manzo Pharmaceuticals, Inc. Website
Source: OTC Markets
Date: October, 31 2016 00:00
Manzo Pharmaceuticals Reports on SEC Settlement with CEO Kenneth Manzo
Manzo Pharmaceuticals Reports on SEC Settlement with CEO Kenneth Manzo
Source: OTC Markets
Date: August, 22 2016 00:00
Manzo Pharmaceuticals, Inc., Reports on Progress with Lacto-Freedom Probiotic
Manzo Pharmaceuticals, Inc., Reports on Progress with Lacto-Freedom Probiotic
Source: OTC Markets
Date: August, 22 2016 00:00
Manzo Pharmaceuticals, Inc announced today that the company's President, Kenneth Manzo, has received a verbal Wells Notice from the US Securities and Exchange Commission.
Manzo Pharmaceuticals, Inc announced today that the company's President, Kenneth Manzo, has received a verbal Wells Notice from the US Securities and Exchange Commission.
Source: OTC Markets
Date: July, 29 2016 00:00
Kenneth Manzo, CEO Manzo Pharmaceuticals, Visited the Probiotic Manufacturing Plant and Was Impressed With the Manufacturer, and Production Has Commenced.
Kenneth Manzo, CEO Manzo Pharmaceuticals, Visited the Probiotic Manufacturing Plant and Was Impressed With the Manufacturer, and Production Has Commenced.
Source: OTC Markets
Date: May, 05 2016 00:00
Manzo Pharmaceuticals solidifies deal with USA based manufacturers to begin producing the company's lactose intolerance probiotic, Lacto-Freedom
Manzo Pharmaceuticals solidifies deal with USA based manufacturers to begin producing the company's lactose intolerance probiotic, Lacto-Freedom
Source: OTC Markets
Date: March, 24 2016 00:00
To create greater value for the shareholders Manzo Pharmaceuticals Inc. has acquired the patent rights from its subsidiary.
To create greater value for the shareholders Manzo Pharmaceuticals Inc. has acquired the patent rights from its subsidiary.
Source: OTC Markets
Date: January, 06 2016 00:00
Manzo Pharmaceuticals human study conducted for Lacto-Freedom showing promising results
Manzo Pharmaceuticals human study conducted for Lacto-Freedom showing promising results
Source: OTC Markets
Date: January, 04 2016 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-200.00010.00010.00010.00011,000
2018-08-170.00010.00010.00010.000110,000
2018-08-160.00010.00010.00010.00012,155,313
2018-08-15N/A0.000001N/AN/A0
2018-08-14N/A0.000001N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-143,301,8466,565,30050.2924Short
2018-03-265,000,0005,000,000100.0000Short
2018-03-025,679,9995,689,99999.8243Short
2018-03-01200,000200,20099.9001Short
2018-02-214,260,9334,580,93393.0145Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MNZO.


About Manzo Pharmaceuticals, Inc. (OTC: MNZO)

Logo for Manzo Pharmaceuticals, Inc. (OTC: MNZO)

Manzo Pharmaceuticals, LLC. is without operations or a material amount of assets. At present, the Issuer intends to start to study ways to increase shareholder value. There is no assurance that the Issuer will be successful in this endeavor.

 

 

 

Current Management

  • Gerasimos Alexander Morfesis / President

Current Share Structure

  • Market Cap: $347,857 - 03/08/2018
  • Authorized: 1,900,000,000 - 03/31/2016
  • Issue and Outstanding: 1,159,522,000 - 03/31/2016
  • Float: 374,243,760 - 03/31/2015

 


Recent Filings from (OTC: MNZO)

Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: September, 20 2016
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: May, 19 2016
Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information
Filing Type: Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current InformFiling Source: OTC Markets
Filing Date: March, 30 2016
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: March, 27 2016
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 12 2015
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: August, 31 2015

 

 


Daily Technical Chart for (OTC: MNZO)

Daily Technical Chart for (OTC: MNZO)


Stay tuned for daily updates and more on (OTC: MNZO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MNZO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MNZO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of MNZO and does not buy, sell, or trade any shares of MNZO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/